Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR 1,748.00
-10.00 (-0.57%)
Oct 23, 2026, 3:28 PM IST
NSE:SUNPHARMA Stock Forecast
Stock Price Forecast
According to 33 analysts polled by S&P Global, NSE:SUNPHARMA stock has a consensus rating of "Buy" and an average price target of ₹2,174. The average 1-year stock price forecast is 24.39% higher than the current stock price, while the lowest is ₹1,830 (+4.69%) and the highest is ₹2,400 (+37.30%).
Price Target: ₹2,174 (+24.39%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Sep 22, 2026.
Analyst Ratings
The average analyst rating for NSE:SUNPHARMA stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 20 | 20 | 19 | 18 | 18 |
| Buy | 10 | 10 | 10 | 10 | 10 | 10 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 2 | 2 | 2 | 3 | 3 | 3 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 34 | 34 | 34 | 34 | 33 | 33 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Geojit Research No rating | Geojit Research | Buy Maintains ₹2,070 | Buy | Maintains | ₹2,070 | +18.42% | Sep 22, 2026 |
Financial Forecast
Revenue This Year
651.11B
from 584.62B
Increased by 11.37%
Revenue Next Year
729.39B
from 651.11B
Increased by 12.02%
EPS This Year
54.68
from 52.01
Increased by 5.13%
EPS Next Year
64.79
from 54.68
Increased by 18.48%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.